Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.07)
# 2,824
Out of 4,843 analysts
107
Total ratings
41.82%
Success rate
-6.66%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: In-Line | $8 → $7 | $6.92 | +1.16% | 3 | May 1, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $165 → $200 | $180.94 | +10.53% | 13 | May 1, 2025 | |
| DGX Quest Diagnostics | Maintains: In-Line | $175 → $180 | $173.34 | +3.84% | 3 | Apr 23, 2025 | |
| HCAT Health Catalyst | Downgrades: In-Line | $6 → $4 | $3.80 | +5.26% | 6 | Apr 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $20 → $15 | $4.30 | +249.24% | 7 | Mar 4, 2025 | |
| MCK McKesson | Maintains: Outperform | $650 → $675 | $719.51 | -6.19% | 5 | Feb 6, 2025 | |
| CVS CVS Health | Maintains: Outperform | $60 → $65 | $64.04 | +1.50% | 6 | Jan 27, 2025 | |
| WBA Walgreens Boots Alliance | Maintains: In-Line | $9 → $12 | $11.25 | +6.67% | 13 | Jan 13, 2025 | |
| LH Labcorp Holdings | Upgrades: Outperform | $260 → $265 | $248.97 | +6.44% | 4 | Jan 7, 2025 | |
| XRAY DENTSPLY SIRONA | Downgrades: In-Line | $20 | $15.98 | +25.16% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $140 | $154.44 | -9.35% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $39.98 | -9.95% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $270 → $265 | $140.33 | +88.84% | 5 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $34 → $45 | $52.09 | -13.61% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $7 → $4 | $2.22 | +80.18% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $23 | $18.27 | +25.89% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $22.76 | -12.13% | 3 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $5.51 | +376.41% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $4.10 | +265.85% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.17 | +406.91% | 2 | Jan 4, 2022 |
Teladoc Health
May 1, 2025
Maintains: In-Line
Price Target: $8 → $7
Current: $6.92
Upside: +1.16%
Align Technology
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $180.94
Upside: +10.53%
Quest Diagnostics
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $173.34
Upside: +3.84%
Health Catalyst
Apr 9, 2025
Downgrades: In-Line
Price Target: $6 → $4
Current: $3.80
Upside: +5.26%
Fortrea Holdings
Mar 4, 2025
Maintains: In-Line
Price Target: $20 → $15
Current: $4.30
Upside: +249.24%
McKesson
Feb 6, 2025
Maintains: Outperform
Price Target: $650 → $675
Current: $719.51
Upside: -6.19%
CVS Health
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $64.04
Upside: +1.50%
Walgreens Boots Alliance
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.25
Upside: +6.67%
Labcorp Holdings
Jan 7, 2025
Upgrades: Outperform
Price Target: $260 → $265
Current: $248.97
Upside: +6.44%
DENTSPLY SIRONA
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $15.98
Upside: +25.16%
Jan 7, 2025
Upgrades: Outperform
Price Target: $140
Current: $154.44
Upside: -9.35%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $39.98
Upside: -9.95%
Oct 8, 2024
Maintains: Outperform
Price Target: $270 → $265
Current: $140.33
Upside: +88.84%
Oct 8, 2024
Maintains: In-Line
Price Target: $34 → $45
Current: $52.09
Upside: -13.61%
Oct 8, 2024
Maintains: In-Line
Price Target: $7 → $4
Current: $2.22
Upside: +80.18%
Sep 23, 2024
Maintains: Outperform
Price Target: $18 → $23
Current: $18.27
Upside: +25.89%
Jul 9, 2024
Maintains: Outperform
Price Target: $23 → $20
Current: $22.76
Upside: -12.13%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $5.51
Upside: +376.41%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $4.10
Upside: +265.85%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.17
Upside: +406.91%